CA2649076A1 - Crystal forms of o-desmethylvenlafaxine - Google Patents
Crystal forms of o-desmethylvenlafaxine Download PDFInfo
- Publication number
- CA2649076A1 CA2649076A1 CA002649076A CA2649076A CA2649076A1 CA 2649076 A1 CA2649076 A1 CA 2649076A1 CA 002649076 A CA002649076 A CA 002649076A CA 2649076 A CA2649076 A CA 2649076A CA 2649076 A1 CA2649076 A1 CA 2649076A1
- Authority
- CA
- Canada
- Prior art keywords
- desmethylvenlafaxine
- crystalline form
- theta
- degrees
- crystalline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- KYYIDSXMWOZKMP-UHFFFAOYSA-N O-desmethylvenlafaxine Chemical compound C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 KYYIDSXMWOZKMP-UHFFFAOYSA-N 0.000 title claims abstract description 51
- 239000013078 crystal Substances 0.000 title description 10
- 238000000034 method Methods 0.000 claims abstract description 62
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 48
- 239000000203 mixture Substances 0.000 claims description 41
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 31
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 26
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 25
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 23
- 239000002904 solvent Substances 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 239000007788 liquid Substances 0.000 claims description 19
- 239000007858 starting material Substances 0.000 claims description 19
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 15
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 13
- 238000009835 boiling Methods 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 12
- 238000002425 crystallisation Methods 0.000 claims description 10
- 230000008025 crystallization Effects 0.000 claims description 10
- 239000000725 suspension Substances 0.000 claims description 10
- 238000005406 washing Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 8
- 238000004090 dissolution Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 238000001157 Fourier transform infrared spectrum Methods 0.000 claims description 6
- 238000002844 melting Methods 0.000 claims description 6
- 230000008018 melting Effects 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 5
- 238000010586 diagram Methods 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 125000003944 tolyl group Chemical group 0.000 claims description 3
- 239000004215 Carbon black (E152) Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 229930195733 hydrocarbon Natural products 0.000 claims description 2
- 150000002430 hydrocarbons Chemical class 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 150000003890 succinate salts Chemical class 0.000 claims description 2
- 239000007787 solid Substances 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000002552 dosage form Substances 0.000 description 10
- 235000019441 ethanol Nutrition 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 8
- 239000008187 granular material Substances 0.000 description 8
- -1 sachets Substances 0.000 description 8
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 7
- 229960004688 venlafaxine Drugs 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 238000007907 direct compression Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 229940032147 starch Drugs 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229940014259 gelatin Drugs 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 235000010981 methylcellulose Nutrition 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 230000000704 physical effect Effects 0.000 description 4
- 239000008247 solid mixture Substances 0.000 description 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 3
- 241000220479 Acacia Species 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 229920002907 Guar gum Polymers 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 239000005913 Maltodextrin Substances 0.000 description 3
- 229920002774 Maltodextrin Polymers 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 239000000783 alginic acid Substances 0.000 description 3
- 229960001126 alginic acid Drugs 0.000 description 3
- 150000004781 alginic acids Chemical class 0.000 description 3
- 229960001631 carbomer Drugs 0.000 description 3
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000010417 guar gum Nutrition 0.000 description 3
- 239000000665 guar gum Substances 0.000 description 3
- 229960002154 guar gum Drugs 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 229940035034 maltodextrin Drugs 0.000 description 3
- 229960002900 methylcellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
- 229960002748 norepinephrine Drugs 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229920003124 powdered cellulose Polymers 0.000 description 3
- 235000019814 powdered cellulose Nutrition 0.000 description 3
- 235000010413 sodium alginate Nutrition 0.000 description 3
- 239000000661 sodium alginate Substances 0.000 description 3
- 229940005550 sodium alginate Drugs 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 229940033134 talc Drugs 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 239000004097 EU approved flavor enhancer Substances 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- ORUUBRMVQCKYHB-UHFFFAOYSA-N butanedioic acid;4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol Chemical compound OC(=O)CCC(O)=O.C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 ORUUBRMVQCKYHB-UHFFFAOYSA-N 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 2
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 2
- 229940082500 cetostearyl alcohol Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- CBOQJANXLMLOSS-UHFFFAOYSA-N ethyl vanillin Chemical group CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000019264 food flavour enhancer Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000193 polymethacrylate Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 239000012439 solid excipient Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- DVVGIUUJYPYENY-UHFFFAOYSA-N 1-methylpyridin-2-one Chemical compound CN1C=CC=CC1=O DVVGIUUJYPYENY-UHFFFAOYSA-N 0.000 description 1
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000206576 Chondrus Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- YIKYNHJUKRTCJL-UHFFFAOYSA-N Ethyl maltol Chemical compound CCC=1OC=CC(=O)C=1O YIKYNHJUKRTCJL-UHFFFAOYSA-N 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- 229920003072 Plasdone™ povidone Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000012615 aggregate Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 229940092782 bentonite Drugs 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229940078456 calcium stearate Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001335 demethylating effect Effects 0.000 description 1
- 229940096516 dextrates Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229940093503 ethyl maltol Drugs 0.000 description 1
- 229940073505 ethyl vanillin Drugs 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
- 229940046813 glyceryl palmitostearate Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 229940043353 maltol Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 230000012154 norepinephrine uptake Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229960000540 polacrilin potassium Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 description 1
- 230000013275 serotonin uptake Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000000176 sodium gluconate Substances 0.000 description 1
- 235000012207 sodium gluconate Nutrition 0.000 description 1
- 229940005574 sodium gluconate Drugs 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 238000002411 thermogravimetry Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- 229940057977 zinc stearate Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/10—Separation; Purification; Stabilisation; Use of additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Abstract
Methods for preparing crystalline forms of O-desmethylvenlafaxine a described.
Description
CRYSTAL FORMS OF O-DESMETHYLVENLAFAX;INE
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] The present application claims the benefit of the following United States Provisional Patent Application Nos.: 60/792,801, filed April 17, 2006;
60/796,739, filed May 1, 2006; 60/899,166, filed February 1, 2007; 60/902,418, filed February 20, 2007; 60/872,955, filed December 4, 2006; and 60/903,988, filed February 27, 2007. The contents of these applications are incorporated herein by reference.
FIELD OF INVENTION
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] The present application claims the benefit of the following United States Provisional Patent Application Nos.: 60/792,801, filed April 17, 2006;
60/796,739, filed May 1, 2006; 60/899,166, filed February 1, 2007; 60/902,418, filed February 20, 2007; 60/872,955, filed December 4, 2006; and 60/903,988, filed February 27, 2007. The contents of these applications are incorporated herein by reference.
FIELD OF INVENTION
[0002] The present invention is directed to a crystalline forms of 0-desmethylvenlafaxine and methods of preparation thereof.
BACKGROUND OF THE INVENTION
BACKGROUND OF THE INVENTION
[0003] Venlafaxine, (-+)-1-[2-(Dimethylamino)-1-(4-ethyoxyphenyl) ethyl]
cyclo- hexanol, having the following fomnula I, is the first of a class of anti-depressants. Venlafaxine acts by inhibiting re-uptake of norepinephrine and serotonin, and is an alternative to the tricyclic anti-depressants and selective re-uptake inhibitors.
HgC"
OH
formula I
cyclo- hexanol, having the following fomnula I, is the first of a class of anti-depressants. Venlafaxine acts by inhibiting re-uptake of norepinephrine and serotonin, and is an alternative to the tricyclic anti-depressants and selective re-uptake inhibitors.
HgC"
OH
formula I
[0004] O-desmethylvenlafaxine, chemically named 4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol and having the following formula II
Oh1 OH
C?6H2sNOZ
Mol. WL:263.3e formula II
is a major metabolite of venlafaxine and has been shown to inhibit norepinephrine and serotonin uptake. Klamerus, K. J. et al., "Introduction of the Composite Parameter to the Pharmacokinetics of Venlafaxine and its Active O-Desmethyl Metabolite", J.
Clin.
Phavrnacol. 32:716-724 (1992).
[0005] O-desmethylvenlafaxine and processes for preparation thereof are described in US patent numbers 6,197,828 and 6,689,912, and in US
2005/0197392, which are incorporated herein by reference.
C?6H2sNOZ
Mol. WL:263.3e formula II
is a major metabolite of venlafaxine and has been shown to inhibit norepinephrine and serotonin uptake. Klamerus, K. J. et al., "Introduction of the Composite Parameter to the Pharmacokinetics of Venlafaxine and its Active O-Desmethyl Metabolite", J.
Clin.
Phavrnacol. 32:716-724 (1992).
[0005] O-desmethylvenlafaxine and processes for preparation thereof are described in US patent numbers 6,197,828 and 6,689,912, and in US
2005/0197392, which are incorporated herein by reference.
[0006] Venlafaxine base can be used as a starting material in the preparation of 0-desmethylvenlafaxine, as demonstrated in US 6,689,912, US 6,197,828, WO
03/048104 and US 2005/0197392.
03/048104 and US 2005/0197392.
[0007] Polymorphism, the occurrence of different crystal forms, is a property of some molecules and molecular complexes. A single molecule, like 0-desmethylvenlafaxine, may give rise to a variety of crystalline forms having distinct crystal structures and physical properties like melting point, x-ray diffraction pattern, infrared absorption fingerprint, FTIl2. spectrum, and solid state NMR
spectrum. One crystalline form may give rise to thermal behavior different from that of another crystalline form. Thermal behavior can be measured in the laboratory by such techniques as capillary melting point, thermogravimetric analysis ("TGA"}, and differential scanning calorimetry ("DSC"), which have been used to distinguish polymorphic forms.
spectrum. One crystalline form may give rise to thermal behavior different from that of another crystalline form. Thermal behavior can be measured in the laboratory by such techniques as capillary melting point, thermogravimetric analysis ("TGA"}, and differential scanning calorimetry ("DSC"), which have been used to distinguish polymorphic forms.
[0008] The difference in the physical properties of different crystalline forms results from the orientation and intermolecular interactions of adjacent molecules or complexes in the bulk solid. Accordingly, polymorphs are distinct solids sharing the same molecular formula yet having distinct advantageous physical properties compared to other crystalline forms of the same compound or complex.
[0009] One of the most important physical properties of pharmaceutical compounds is their solubility in aqueous solution, particularly their solubility in the gastric juices of a patient. For example, where absorption through the gastrointestinal tract is slow, it is o$en desirable for a drug that is unstable to conditions in the patient's stomach or intestine to dissolve slowly so that it does not accumulate in a deleterious environment. Different crystalline forms or polymorphs of the same pharmaceutical compounds can and reportedly do have different aqueous solubilities.
[00010] The discovery of new polymorphic forms of a pharmaceutically useful compound provides a new opportunity to improve the performance characteristics of a pharrnaceutical product. It enlarges the repertoire of materials that a formulation scientist has available for designing, for example, a pharmaceutical dosage form of a drug with a targeted release profile or other desired characteristic.
[00011] There is a need in the art for polymorphic forms of 0-desmethylvenlafaxine.
SUMMARY OF THE INVENTION
SUMMARY OF THE INVENTION
[00012] In one embodiment, the present invention provides a method of preparing a crystalline form of 0-desmethylvenlafaxine characterized by X-ray powder diffraction reflections at about: 12.1, 13.2, 15.9 and 20.4 degrees two theta t 0.2 degrees two theta by crystallization from a solvent selected from the group consisting of: ethanol, tetrahydrofuran. (THF), isopropyl alcohol (IPA) and a mixture of IPA and water. Preferably, the method of preparing a crystalline form of 0-desmethylvenlafaxine by crystallization from ethanol also comprises washing with an appropriate washing liquid. More preferably, the washing liquid is heptane.
[00013] In another embodiment, the present invention provides a crystalline form of 0-desmethylvenlafaxine, characterized by X-ray powder diffraction reflections at about: 13.1, 16.2, 19.8, 20.6 and 22.2 degrees two theta f 0.2 degrees two theta.
[00014] In another embodiment, the present invention provides a crystalline form of 0-desmethylvenlafaxine, characterized by X-ray powder diffraction reflections at about: 12.2, 13.3, 18.1 and 19.7 degrees two theta f 0.2 degrees two theta.
[00015] In another embodiment, the present invention provides pharmaceutical compositions comprising at least one of the above crystal forms of 0-desmethylvenlafaxine and a pharmaceutically acceptable excipient.
[00016] In another embodiment, the present invention provides a process for preparing a pharmaceutical composition comprising at least one of the crystalline forms of 0-desmethylvenlafaxine of the present invention and a pharmaceutically acceptable excipient.
[00017] In yet another embodiment, the present invention provides pharmaceutical formulations comprising at least one of the crystalline forms of 0-desmethylvenlafaxine prepared according to the processes of the present invention, and a pharmaceutically acceptable excipient.
(00018] In another embodiment, the present invention provides a process for preparing pharznaceutical formulations comprising at least one of the crystalline forms of 0-desmethylvenlafaxine prepared according to the processes of the present invention, and a pharmaceutically acceptable excipient.
[00019] In another embodiment, the present invention provides a method of treating a patient comprising administering to a patient in need thereof a therapeutically effective amount of the above crystalline forms of 0-desmethylvenlafaxine.
BRIEF DESCRIPTION OF THE FIGURES
BRIEF DESCRIPTION OF THE FIGURES
[00020] Figure 1 shows a FTIR spectrum of form A of 0-desmethylvenlafaxine.
[00021] Figure 2 shows a PXRD for form A of 0-desmethylvenlafaxine.
[00022] Figure 3 shows a PXRD for crystalline form C of 0-desmethylvenlafaxine.
[00023] Figure 4 shows a PXRD for crystalline form D of 0-desmethylvenlafaxine.
DETAILED DESCRIPTION OF THE INVENTION
DETAILED DESCRIPTION OF THE INVENTION
[00024] In one embodiment, the present invention provides a method of preparing a crystalline form of 0-desmethylvenlafaxine characterized by X-ray powder diffraction reflections at about: 12.1, 13.2, 15.9 and 20.4 degrees two theta f 0.2 degrees two theta by crystallization from a solvent selected from the group consisting of: ethanol, tetrahydrofuran (THF), isopropyl alcohol (IPA) and a mixture of IPA and water.
[00025] When ethanol is used as a crystallization solvent, preferably, absolute ethanol is used.
[00025] When ethanol is used as a crystallization solvent, preferably, absolute ethanol is used.
[00026] The crystalline form may then be recovered by any method known in the art, such as washing the particles. Preferably, the particles crystallized from ethanol are washed with an appropriate washing liquid. More preferably the washing liquid is a C5-C8 hydrocarbon, such as heptane.
[00027] The method of the present invention for preparing a crystalline form of 0-desmethylvenlafaxine characterized by X-ray powder diffraction reflections at about: 12.1, 13.2, 15.9 and 20.4 degrees two theta =L- 0.2 degrees two theta comprises;
a) combining 0-desmethylvenlafaxine starting material and a solvent selected from the group consisting of ethanol, tetrahydrofuran (THF), isopropyl alcohol (IPA) and a mixture of IPA and water to form a mixture; b) heating the mixture at a temperature and for a sufficient period to obtain dissolution, preferably at about 50 C to about 100 C, more preferably at 60 C to about 80 C; and c) recovering the crystalline 0-desmethylvenlafaxine.
a) combining 0-desmethylvenlafaxine starting material and a solvent selected from the group consisting of ethanol, tetrahydrofuran (THF), isopropyl alcohol (IPA) and a mixture of IPA and water to form a mixture; b) heating the mixture at a temperature and for a sufficient period to obtain dissolution, preferably at about 50 C to about 100 C, more preferably at 60 C to about 80 C; and c) recovering the crystalline 0-desmethylvenlafaxine.
[00028] Preferably, the heating step comprises refluxing the mixture for a sufficient time to effect complete dissolution of the O-desmethylvenlafaxine starting material.
[00029] In this process of the present invention heating may comprise evaporating the solvent.
[00030] The crystalline form of 0-desmethylvenlafaxine characterized by X-ray powder diffraction reflections at about 12.1, 13.2, 15.9, and 20.4 degrees two theta :E 0.2 degrees two theta is denominated form A. Crystalline 0-desmethylvenlafaxine form A may be further characterized by a FTIR spectrum having peaks at about 844, 1276, 1517, and 1619 cm 1. A FTIR spectrum of crystalline 0-desmethylvenlafaxine form A may further contain peaks at about 1148, 1240, 1447, 1460, 2834, and cm l, or is substantially as depicted in Figure 1.
[00031] The 0-desmethylvenlafaxine starting material can be obtained by any method known in the art, such as the one described in US 6,197,828, which is incorporated herein by reference. Preferably, the 0-desmethylvenlafaxine is obtained in a process comprising demethylating venlafaxine base as described in the following scheme:
NMe2 NMe2 OH OH
L-Selectride Me0 THF HO
Venlafaxine base O-desmethylvenlafaxine [00032] In another embodiment, the present invention provides a crystalline form of 0-desmethylvenlafaxine, characterized by X-ray powder diffraction reflections at about: 13.1, 16.2, 19.8, 20.6 and 22.2 degrees two theta + 0.2 degrees two theta. This form is denominated Form C.
NMe2 NMe2 OH OH
L-Selectride Me0 THF HO
Venlafaxine base O-desmethylvenlafaxine [00032] In another embodiment, the present invention provides a crystalline form of 0-desmethylvenlafaxine, characterized by X-ray powder diffraction reflections at about: 13.1, 16.2, 19.8, 20.6 and 22.2 degrees two theta + 0.2 degrees two theta. This form is denominated Form C.
[00033] Form C can be further characterized by X-ray powder diffraction peaks at about 12.2; 15.6 and 26.2 degrees two-theta, +_ 0.2 degrees two-theta. A
powder x-ray diffraction diagram of Form C is given in Figure 3.
powder x-ray diffraction diagram of Form C is given in Figure 3.
[00034] In another embodiment, the present invention provides a process for the crystallization of 0-desmethylvenlafaxine Form C from a high boiling point solvent. The starting material for this crystallization to obtain 0-desmethylvenlafaxine Form C may be a 0-desmethylvenlafaxine salt, preferably the starting material for crystallization of Form C from toluene is the succinate salt of 0-desmethylvenlafaxine, more preferably O-desmethylvenlafaxine succinate characterized by X-ray powder diffraction peaks at about 13.18, 14.04, 14.35, 14.66, 16.68, 17.67, 19.24, 25.13, and 31.78, (Form II).
[0003-5] The 0-desmethylvenlafaxine succinate starting material can be obtained by any method known in the art, such as the one described in US
6,673,838, which is incorporated herein by reference.
[00036] As used herein, the tertn "high boiling point solvent" refers to a solvent having a boiling point higher than about 100 C. Preferably., the high boiling point solvent is selected from the group consisting of: toluene, dimethylformamide (DMF), dimethylsulfoxide (DMSO), N-methyl-2-pyridone, N-methyl-2-pyrrolidone, 1-methyl-2-pyrolidinone (NMP) and dimethylacetamide (DMA). More preferably, the high boiling point solvent is toluene.
[00037] Crystallization of this form of 0-desmethylvenlafaxine may be carried out by dissolving 0-desmethylvenlafaxine in a high boiling point solvent by heating a suspension of 0-desmethylvenlafaxine starting material with a high boiling point solvent, cooling the obtained solution to a temperature of about 15 C to about and maintaining the cooled solution at this temperature for a period of time, followed by recovering the crystalline 0-desmethylvenlafaxine. Preferably the suspension is heated to a temperature of about 100 C to about 110 C, more preferably to about reflux. The obtained solution is preferably cooled to a temperature of about 15 C to about 3.0 C, more preferably to about room temperature, and preferably maintained at this temperature for a period of at least about 30 minutes, preferably about 30 minutes to about 1 hour.
[00038] In a preferred method, the reaction occurs while stirring at about room temperature for at least about 30 minutes, preferably about 30 minutes to about 1 hour.
[00039] Form C may then be recovered by any methods known in the art.
[00040] In one embodiment, the present invention provides a process for preparing 0-desmethylvenlafaxine Form C which comprises heating 0-desmethylvenlafaxine, followed by, cooling the compound.
(00041] Preferably, heating is carried out to achieve melting of the compound.
[00042] Preferably, the compound is cooled to a temperature of from about 0 C
to about room temperature, more preferably to a temperature of about 5 C to about 25 C.
[00043] The 0-desmethylvenlafaxine starting material can be obtained as described above.
[00044] In another embodiment, the present invention provides a crystalline form of 0-desmethylvenlafaxine, characterized by X-ray powder diffraction reflections at about: 12.2, 13.3, 18.1 and 19.7 degrees two theta ~ 0.2 degrees two theta. This form is denominated Form D.
[00045] Form D can be further characterized by X-ray powder diffraction peaks at about 22.5, 25.3 and 28.7 degrees two-theta, f 0.2 degrees two-theta. A
powder x-ray diffraction diagram of Form D is given in Figure 4.
[00046] In another embodiment, the present invention provides a process for preparing 0-desmethylvenlafaxine Form D which comprises suspending 0-desmethylvenlafaxine in N-methylpyrrolidinone (NMP). Preferably, the O-desmethylvenlafaxine is suspended at a temperature of about 15 C to about 30 C, more preferably at a temperature of about room temperature. The suspension may be maintained at such temperature for a period of about 24 hours to about 48 hours, more preferably for about 32 hours to about 48 hours, to obtain crystalline 0-desmethylvenlafaxine.
[00047] The 0-desmethylvenlafaxine starting material is preferably crystalline.
More preferably, the 0-desmethylvenlafaxine starting material is Form A of 0-desmethylvenlafaxine, as defined above.
[00048] Preferably, the 0-desmethylvenlafaxine is wetted with 2-3 drops of NMP and is preferably maintained at room temperature for about 48 hours, to obtain 0-desmethylvenlafaxine Form D.
[00049] In another embodiment, the present invention provides pharmaceutical compositions comprising at least one of the above crystal forms of 0-desmethylvenlafaxine or a combination thereof and a pharmaceutically acceptable exipient.
[00050] In another embodiment, the present invention provides a process. for preparing a pharmaceutical composition comprising at least one of the crystalline forms of 0-desmethylvenlafaxine of the present invention and a pharmaceutically acceptable excipient.
[00051] In yet another embodiment, the present invention provides pharmaceutical formulations comprising at least one of the crystalline forms of 0-desmethylvenlafaxine prepared according to the processes of the present -invention, and a pharmaceutically acceptable excipient.
[00052] In another embodiment, the present invention provides a process for preparing pharmaceutical formulations comprising at least one of the crystalline forms of 0-desmethylvenlafaxine prepared according to the processes of the present invention, and a pharrnaceutically acceptable excipient.
[00053] Pharmaceutical compositions may be prepared as medicaments to be administered orally, parenterally, rectally, transdermally, bucally, or nasally. Suitable forms for oral administration include tablets, compressed or coated pills, dragees, sachets, hard or gelatin capsules, sub-lingual tablets, syrups, and suspensions.
Suitable forms of parenteral administration include an aqueous or non-aqueous solution or emulsion, while for rectal administration, suitable forms for administration include suppositories with hydrophilic or hydrophobic vehicle. For topical administration, the invention provides suitable transdermal delivery systems known in the art, and for nasal delivery, there are provided suitable aerosol delivery systems known in the art.
[00054] In addition to the active ingredient(s), the pharmaceutical compositions of the present invention may contain one or more excipients or adjuvants.
Selection of excipients and the amounts to use may be readily determined by the formulation scientist based upon experience and consideration of standard procedures and reference works in the field.
[00055] Diluents increase the bulk of a solid pharmaceutical composition, and may make a pharrnaceutical dosage form containing the composition easier for the patient and care giver to handle. Diluents for solid compositions include, for example, microcrystalline cellulose (e.g. Avicel ), microfine cellulose, lactose, starch, pregelitinized starch, calcium carbonate, calcium sulfate, sugar, dextrates, dextrin, dextrose, dibasic calcium phosphate dihydrate, tribasic calcium phosphate, kaolin, magnesium carbonate, magnesium oxide, maltodextrin, mannitol, polymethacrylates (e.g. Eudragit), potassium chloride, powdered cellulose, sodium chloride, sorbitol, and talc.
[00056] Solid pharmaceutical compositions that are compacted into a dosage form, such as a tablet, may include excipients whose functions include helping. to bind the active ingredient and other excipients together after compression. Binders for solid-pharmaceutical compositions include acacia, alginic acid, carbomer (e.g_ carbopoI), carboxymethylcellulose sodium, dextrin, ethyl cellulose, gelatin, guar gum, hydrogenated vegetable oil, hydroxyethyl cellulose, hydroxypropyl cellulose (e.g.
Klucel ), hydroxypropyl methyl cellulose (e.g. Methocel ), liquid glucose, magnesium aluminum silicate, maltodextrin, methylcellulose, polymethacrylates, povidone (e.g. Kollidon , Plasdone'~'), pregelatinized starch, sodium alginate, and starch.
[00057] The dissolution rate of a compacted solid pharmaceutical composition in the patient's stomach may be increased by the addition of a disintegrant to the composition. Disintegrants include alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium (e.g. Ac-Di-Solo, Primellosell'), colloidal silicon dioxide, croscarmellose sodium, crospovidone (e.g. Kollidon , Polyplasdone ), guar gum, magnesium aluminum silicate, methyl cellulose, microcrystalline cellulose, polacrilin potassium, powdered cellulose, pregelatinized starch, sodium alginate, sodium starch glycolate (e.g. Explotab'~), and starch.
[00058] Glidants can be added to improve the flowability of a non-compacted solid composition and to improve the accuracy of dosing. Excipients that may function as glidants include colloidal silicon dioxide, magnesium trisilicate, powdered cellulose, starch, talc, and tribasic calcium phosphate.
[00059] When a dosage form such as a tablet is made by the compaction of a powdered composition, the composition is subjected to pressure from a punch and die.
Some excipients and active ingredients have a tendency to adhere to the surfaces of the punch and die, which can cause the product to have pitting and other surface irregularities. A lubricant can be added to the composition to reduce adhesion and ease the release of the product from the die. Lubricants include magnesium stearate, calcium stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, mineral oil, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc, and zinc stearate.
[00060] Flavoring agents and flavor enhancers make the dosage form more palatable to the patient. Common flavoring agents and flavor enhancers for pharmaceutical products that may be included in the composition of the present invention include maltol, vanillin, ethyl vanillin, menthol, citric acid, fumaric acid, ethyl maltol, and tartaric acid.
[00061] Solid and liquid compositions may also.be dyed using any pharmaceutically acceptable colorant to improve their appearance and/or facilitate patient identification of the product and unit dosage level.
[00062] In liquid pharmaceutical compositions of the present invention, the active ingredient and any other solid excipients are suspended in a liquid carrier such as water, vegetable oil, alcohol, polyethylene glycol, propylene glycol or glycerin. In such suspension the solid excipients may be either in solution or suspended in the liquid carrier. The active ingredient retains its crystalline structure in such liquid phannaceutical compositions.
[00063] Liquid pharmaceutical compositions may contain emulsifying agents to disperse uniformly throughout the composition an active ingredient or other excipient that is not soluble in the liquid carrier. Emulsifying agents that may be useful in liquid compositions of the present invention include, for example, gelatin, egg yolk, casein, cholesterol, acacia, tragacanth, chondrus, pectin, methyl cellulose, carbomer, cetostearyl alcohol, and cetyl alcohol.
[00064] Liquid pharmaceutical compositions of the present invention may also contain a viscosity enhancing agent to improve the mouth-feel of the product and/or coat the lining of the gastrointestinal tract. Such agents include acacia, alginic acid bentonite, carbomer, carboxymethylcellulose calcium or sodium, cetostearyl alcohol, methyl cellulose, ethylcellulose, gelatin guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, maltodextrin, polyvinyl alcohol, povidone, propylene carbonate, propylene glycol alginate, sodium alginate, sodium starch glycolate, starch tragacanth, and xanthan gum.
[00065] Sweetening agents such as sorbitol, saccharin, sodium saccharin, sucrose, aspartame, fructose, mannitol, and invert sugar may be added to improve the taste.
[00066] Preservatives. and chelating agents such as alcohol, sodium benzoate, butylated hydroxy toluene, butylated hydroxyanisole, and ethylenediamine tetraacetic acid may be added at levels safe for ingestion to improve storage stability.
[00067] According to the present invention, a liquid composition may also contain a buffer such as -gluconic acid, lactic acid, citric acid or acetic acid, sodium gluconate, sodium lactate, sodium citrate, or sodium acetate.
[00068] Selection of excipients and the amounts used may be readily determined by the formulation scientist based upon experience and consideration of standard procedures and reference works in the field.
[00069] The solid compositions of the present invention include powders, granulates, aggregates, and compacted compositions. The dosages include dosages suitable for oral, buccal, rectal, parenteral (including subcutaneous, intramuscular, and intravenous), inhalant, and ophthalmic administration. Although the most suitable administration in any given case will depend on the nature and severity of the condition being treated, the most preferred route of the present invention is oral. The dosages may be conveniently presented in unit dosage form and prepared by any of the methods well known in the pharmaceutical arts.
[00070] Dosage forms include solid dosage forms like tablets, powders, capsules, suppositories, sachets, troches, and losenges, as well as liquid syrups, suspensions, and elixirs.
[00071] The dosage form of the present invention may be a capsule containing the composition, preferably a powdered or granulated solid composition of the invention, within either a hard or soft shell. The shell may be made from gelatin, and, optionally, contain a plasticizer such as glycerin and sorbitol, and an opacifying agent or colorant.
[00072] The active ingredient and excipients may be formulated into compositions and dosage forms according to methods known in the art.
[00073] A composition for tableting or capsule filling may be prepared by wet granulation. In wet granulation, some or all of the active ingredients and excipients in powder form are blended, and then further mixed in the presence of a liquid, typically water, that causes the powders to clump into granules. The granulate is screened and/or milled, dried, and then screened and/or milled to the desired particle size. The granulate may then be tableted or other excipients may be added prior to tableting, such as a glidant and/or a lubricant.
[00074] A tableting composition may be prepared conventionally by dry blending. For example, the blended composition of the actives and excipients may be compacted into a slug or a sheet, and then comminuted into compacted granules.
The compacted granules may subsequently be compressed into a tablet.
[00075] As an alternative to dry granulation, a blended composition may be compressed directly into a compacted dosage form using direct compression techniques. Direct compression produces a more uniform tablet without granules.
Excipients that are particularly well suited for direct compression tableting include microcrystalline cellulose, spray dried lactose, dicalcium phosphate dihydrate and colloidal silica. The proper use of these and other excipients in direct compression tableting is known to those in the art with experience and skill in particular formulation challenges of direct compression tableting.
[00076] A capsule filling of the present invention may comprise any of the aforementioned blends and granulates that were described with reference to tableting, however, they are not subjected to a final tableting step.
[00077] In another embodiment, the present invention provides a method of treating a patient comprising administering to a patient in need thereof a therapeutically effective amount of the above crystalline form of 0-desmethylvenlafaxine. Preferably, the patient suffers from a condition which may be treated with a norepinephrine or a serotonin re-uptake inhibitor. Such patient may be suffering from depression.
[00078] Having described the invention with reference to certain preferred embodiments, other embodiments will become apparent to one skilled in the art from consideration of the specification. The disclosures of the references referred to in this patent application are incorporated herein by reference. The invention is further defined by reference to the following examples describing in detail the process and compositions of the invention. It will be apparent to those skilled in the art that many modifications, both to materials and methods, may be practiced without departing from the scope of the invention.
EXAMPLES
[00079] The XRD diffraction was performed on Scintag X-ray powder diffractometer model X'TRA with a solid state detector. Copper radiation of 1.5418 A was used. The sample holder was a round standard aluminum sample holder with rough zero background. The scanning parameters were range: 2-40 degrees two-theta; scan mode: continuous scan; step size: 0.05 deg.; and at a rate of 5 deg/min.
Preparation of 0-desmethylvenlafaxine Example 1 [00080] A mixture of Venlafaxine (5.7g, 20.4 mmol) and L-Selectride, 1.0 M
solution in THF (61 m1, 61 mmol) was refluxed for about 48 hours. Methanol (30ml) was added dropwise to the stirred mixture at 0-5 C (ice/water bath), the mixture was evaporated under xeduced pressure and Hydrochloric acid, 5% aq. solution (125m1) was added to the residue. The mixture was extracted with Ethyl acetate (3x40m1), an aqueous layer was basified with 21% aq. solution of Sodium hydroxide to pH 11, filtered and washed with Ethyl acetate (3x30rn1) to give a residue (4.0g).
Preparation of 0-desmethylvenlafaxine crystal form A
Example 2 [00081] 5g of 0-desmethylvenlafaxine was crystallized from abs. Ethanol and washed with Heptane (3x30m1) to give 1.6g (30_0%) of O-Desmethylvenlafaxine as white crystals with mp 222.2-223 C and 99.17% purity by HPLC.
Example 3 [00082] A 500 ml flask equipped with a condenser and a mechanical stirrer was charged with 0-desmethylvenlafaxine base (17.5g) and IPA (450 ml). The mixture was heated to reflux until complete dissolution. The solution was then slowly cooled to 5 C and maintained at this temperature for 2 hours. The solid was filtered under reduced pressure and ciried overnight under vacuuixi at 60 C to get pure O-desmethylvenlafaxine base (15.63, 89.3%). BPLC analysis 99.95%
Exarnple 4 [00083] A 100 ml flask equipped with mechanical stirrer was charged with 0-desmethylvenlafaxine (1 g) and THF (100 ml) at ambient temperature for 20 minutes.
The solution was filtered and evaporated at 40 C under reduced pressure to get pure 0-desmethylvenlafaxine base form A.
Preparation of 0-desmethylvenlafaxine crystal forrn C
Example 5 [00084] O-desmethylvenlafaxine Succinate (0.5g, form II) and toluene (7.5m1) were put in 25m1 flask with magnetic stirrer. The suspension was heated to reflux until almost complete dissolution. The fine particles present were decanted and the clear solution was cooled to room temperature over 30 minutes to 1 hour. The solution was stirred at this temperature for ihour. The solid that appeared was then filtered under reduced pressure. The wet sample was analyzed by XRD and found to be form C. The solid was dried few hours at 50 C under vacuum and analyzed by XRD. The solid was found to be form C.
Example 6 [00085] 0.5g of O-desmethylvenlafaxine base was heated in a test tube until melting. The melted compound was then cooled to ambient temperature. The compound so-obtained was analyzed by XRD and found to be form C.
Example 7 [00086] O.Sg of 0-desmethylvenlafaxine base was heated in a test tube until melting. The melted compound was poured into ice-cold water. The compound so-obtained was analyzed by XRD and found to be form C.
Preparation of 0-desmethylvenlafaxine crystal form D
Example 8 [00087] A 100 ml flask equipped with mechanical stirrer was charged with 0-desmethylvenlafaxine (1 g) and N-methylpyrrolidinone (3 drops) at ambient temperature over week-end. The solid was then analyzed by XRD and found to be form D.
[0003-5] The 0-desmethylvenlafaxine succinate starting material can be obtained by any method known in the art, such as the one described in US
6,673,838, which is incorporated herein by reference.
[00036] As used herein, the tertn "high boiling point solvent" refers to a solvent having a boiling point higher than about 100 C. Preferably., the high boiling point solvent is selected from the group consisting of: toluene, dimethylformamide (DMF), dimethylsulfoxide (DMSO), N-methyl-2-pyridone, N-methyl-2-pyrrolidone, 1-methyl-2-pyrolidinone (NMP) and dimethylacetamide (DMA). More preferably, the high boiling point solvent is toluene.
[00037] Crystallization of this form of 0-desmethylvenlafaxine may be carried out by dissolving 0-desmethylvenlafaxine in a high boiling point solvent by heating a suspension of 0-desmethylvenlafaxine starting material with a high boiling point solvent, cooling the obtained solution to a temperature of about 15 C to about and maintaining the cooled solution at this temperature for a period of time, followed by recovering the crystalline 0-desmethylvenlafaxine. Preferably the suspension is heated to a temperature of about 100 C to about 110 C, more preferably to about reflux. The obtained solution is preferably cooled to a temperature of about 15 C to about 3.0 C, more preferably to about room temperature, and preferably maintained at this temperature for a period of at least about 30 minutes, preferably about 30 minutes to about 1 hour.
[00038] In a preferred method, the reaction occurs while stirring at about room temperature for at least about 30 minutes, preferably about 30 minutes to about 1 hour.
[00039] Form C may then be recovered by any methods known in the art.
[00040] In one embodiment, the present invention provides a process for preparing 0-desmethylvenlafaxine Form C which comprises heating 0-desmethylvenlafaxine, followed by, cooling the compound.
(00041] Preferably, heating is carried out to achieve melting of the compound.
[00042] Preferably, the compound is cooled to a temperature of from about 0 C
to about room temperature, more preferably to a temperature of about 5 C to about 25 C.
[00043] The 0-desmethylvenlafaxine starting material can be obtained as described above.
[00044] In another embodiment, the present invention provides a crystalline form of 0-desmethylvenlafaxine, characterized by X-ray powder diffraction reflections at about: 12.2, 13.3, 18.1 and 19.7 degrees two theta ~ 0.2 degrees two theta. This form is denominated Form D.
[00045] Form D can be further characterized by X-ray powder diffraction peaks at about 22.5, 25.3 and 28.7 degrees two-theta, f 0.2 degrees two-theta. A
powder x-ray diffraction diagram of Form D is given in Figure 4.
[00046] In another embodiment, the present invention provides a process for preparing 0-desmethylvenlafaxine Form D which comprises suspending 0-desmethylvenlafaxine in N-methylpyrrolidinone (NMP). Preferably, the O-desmethylvenlafaxine is suspended at a temperature of about 15 C to about 30 C, more preferably at a temperature of about room temperature. The suspension may be maintained at such temperature for a period of about 24 hours to about 48 hours, more preferably for about 32 hours to about 48 hours, to obtain crystalline 0-desmethylvenlafaxine.
[00047] The 0-desmethylvenlafaxine starting material is preferably crystalline.
More preferably, the 0-desmethylvenlafaxine starting material is Form A of 0-desmethylvenlafaxine, as defined above.
[00048] Preferably, the 0-desmethylvenlafaxine is wetted with 2-3 drops of NMP and is preferably maintained at room temperature for about 48 hours, to obtain 0-desmethylvenlafaxine Form D.
[00049] In another embodiment, the present invention provides pharmaceutical compositions comprising at least one of the above crystal forms of 0-desmethylvenlafaxine or a combination thereof and a pharmaceutically acceptable exipient.
[00050] In another embodiment, the present invention provides a process. for preparing a pharmaceutical composition comprising at least one of the crystalline forms of 0-desmethylvenlafaxine of the present invention and a pharmaceutically acceptable excipient.
[00051] In yet another embodiment, the present invention provides pharmaceutical formulations comprising at least one of the crystalline forms of 0-desmethylvenlafaxine prepared according to the processes of the present -invention, and a pharmaceutically acceptable excipient.
[00052] In another embodiment, the present invention provides a process for preparing pharmaceutical formulations comprising at least one of the crystalline forms of 0-desmethylvenlafaxine prepared according to the processes of the present invention, and a pharrnaceutically acceptable excipient.
[00053] Pharmaceutical compositions may be prepared as medicaments to be administered orally, parenterally, rectally, transdermally, bucally, or nasally. Suitable forms for oral administration include tablets, compressed or coated pills, dragees, sachets, hard or gelatin capsules, sub-lingual tablets, syrups, and suspensions.
Suitable forms of parenteral administration include an aqueous or non-aqueous solution or emulsion, while for rectal administration, suitable forms for administration include suppositories with hydrophilic or hydrophobic vehicle. For topical administration, the invention provides suitable transdermal delivery systems known in the art, and for nasal delivery, there are provided suitable aerosol delivery systems known in the art.
[00054] In addition to the active ingredient(s), the pharmaceutical compositions of the present invention may contain one or more excipients or adjuvants.
Selection of excipients and the amounts to use may be readily determined by the formulation scientist based upon experience and consideration of standard procedures and reference works in the field.
[00055] Diluents increase the bulk of a solid pharmaceutical composition, and may make a pharrnaceutical dosage form containing the composition easier for the patient and care giver to handle. Diluents for solid compositions include, for example, microcrystalline cellulose (e.g. Avicel ), microfine cellulose, lactose, starch, pregelitinized starch, calcium carbonate, calcium sulfate, sugar, dextrates, dextrin, dextrose, dibasic calcium phosphate dihydrate, tribasic calcium phosphate, kaolin, magnesium carbonate, magnesium oxide, maltodextrin, mannitol, polymethacrylates (e.g. Eudragit), potassium chloride, powdered cellulose, sodium chloride, sorbitol, and talc.
[00056] Solid pharmaceutical compositions that are compacted into a dosage form, such as a tablet, may include excipients whose functions include helping. to bind the active ingredient and other excipients together after compression. Binders for solid-pharmaceutical compositions include acacia, alginic acid, carbomer (e.g_ carbopoI), carboxymethylcellulose sodium, dextrin, ethyl cellulose, gelatin, guar gum, hydrogenated vegetable oil, hydroxyethyl cellulose, hydroxypropyl cellulose (e.g.
Klucel ), hydroxypropyl methyl cellulose (e.g. Methocel ), liquid glucose, magnesium aluminum silicate, maltodextrin, methylcellulose, polymethacrylates, povidone (e.g. Kollidon , Plasdone'~'), pregelatinized starch, sodium alginate, and starch.
[00057] The dissolution rate of a compacted solid pharmaceutical composition in the patient's stomach may be increased by the addition of a disintegrant to the composition. Disintegrants include alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium (e.g. Ac-Di-Solo, Primellosell'), colloidal silicon dioxide, croscarmellose sodium, crospovidone (e.g. Kollidon , Polyplasdone ), guar gum, magnesium aluminum silicate, methyl cellulose, microcrystalline cellulose, polacrilin potassium, powdered cellulose, pregelatinized starch, sodium alginate, sodium starch glycolate (e.g. Explotab'~), and starch.
[00058] Glidants can be added to improve the flowability of a non-compacted solid composition and to improve the accuracy of dosing. Excipients that may function as glidants include colloidal silicon dioxide, magnesium trisilicate, powdered cellulose, starch, talc, and tribasic calcium phosphate.
[00059] When a dosage form such as a tablet is made by the compaction of a powdered composition, the composition is subjected to pressure from a punch and die.
Some excipients and active ingredients have a tendency to adhere to the surfaces of the punch and die, which can cause the product to have pitting and other surface irregularities. A lubricant can be added to the composition to reduce adhesion and ease the release of the product from the die. Lubricants include magnesium stearate, calcium stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, mineral oil, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc, and zinc stearate.
[00060] Flavoring agents and flavor enhancers make the dosage form more palatable to the patient. Common flavoring agents and flavor enhancers for pharmaceutical products that may be included in the composition of the present invention include maltol, vanillin, ethyl vanillin, menthol, citric acid, fumaric acid, ethyl maltol, and tartaric acid.
[00061] Solid and liquid compositions may also.be dyed using any pharmaceutically acceptable colorant to improve their appearance and/or facilitate patient identification of the product and unit dosage level.
[00062] In liquid pharmaceutical compositions of the present invention, the active ingredient and any other solid excipients are suspended in a liquid carrier such as water, vegetable oil, alcohol, polyethylene glycol, propylene glycol or glycerin. In such suspension the solid excipients may be either in solution or suspended in the liquid carrier. The active ingredient retains its crystalline structure in such liquid phannaceutical compositions.
[00063] Liquid pharmaceutical compositions may contain emulsifying agents to disperse uniformly throughout the composition an active ingredient or other excipient that is not soluble in the liquid carrier. Emulsifying agents that may be useful in liquid compositions of the present invention include, for example, gelatin, egg yolk, casein, cholesterol, acacia, tragacanth, chondrus, pectin, methyl cellulose, carbomer, cetostearyl alcohol, and cetyl alcohol.
[00064] Liquid pharmaceutical compositions of the present invention may also contain a viscosity enhancing agent to improve the mouth-feel of the product and/or coat the lining of the gastrointestinal tract. Such agents include acacia, alginic acid bentonite, carbomer, carboxymethylcellulose calcium or sodium, cetostearyl alcohol, methyl cellulose, ethylcellulose, gelatin guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, maltodextrin, polyvinyl alcohol, povidone, propylene carbonate, propylene glycol alginate, sodium alginate, sodium starch glycolate, starch tragacanth, and xanthan gum.
[00065] Sweetening agents such as sorbitol, saccharin, sodium saccharin, sucrose, aspartame, fructose, mannitol, and invert sugar may be added to improve the taste.
[00066] Preservatives. and chelating agents such as alcohol, sodium benzoate, butylated hydroxy toluene, butylated hydroxyanisole, and ethylenediamine tetraacetic acid may be added at levels safe for ingestion to improve storage stability.
[00067] According to the present invention, a liquid composition may also contain a buffer such as -gluconic acid, lactic acid, citric acid or acetic acid, sodium gluconate, sodium lactate, sodium citrate, or sodium acetate.
[00068] Selection of excipients and the amounts used may be readily determined by the formulation scientist based upon experience and consideration of standard procedures and reference works in the field.
[00069] The solid compositions of the present invention include powders, granulates, aggregates, and compacted compositions. The dosages include dosages suitable for oral, buccal, rectal, parenteral (including subcutaneous, intramuscular, and intravenous), inhalant, and ophthalmic administration. Although the most suitable administration in any given case will depend on the nature and severity of the condition being treated, the most preferred route of the present invention is oral. The dosages may be conveniently presented in unit dosage form and prepared by any of the methods well known in the pharmaceutical arts.
[00070] Dosage forms include solid dosage forms like tablets, powders, capsules, suppositories, sachets, troches, and losenges, as well as liquid syrups, suspensions, and elixirs.
[00071] The dosage form of the present invention may be a capsule containing the composition, preferably a powdered or granulated solid composition of the invention, within either a hard or soft shell. The shell may be made from gelatin, and, optionally, contain a plasticizer such as glycerin and sorbitol, and an opacifying agent or colorant.
[00072] The active ingredient and excipients may be formulated into compositions and dosage forms according to methods known in the art.
[00073] A composition for tableting or capsule filling may be prepared by wet granulation. In wet granulation, some or all of the active ingredients and excipients in powder form are blended, and then further mixed in the presence of a liquid, typically water, that causes the powders to clump into granules. The granulate is screened and/or milled, dried, and then screened and/or milled to the desired particle size. The granulate may then be tableted or other excipients may be added prior to tableting, such as a glidant and/or a lubricant.
[00074] A tableting composition may be prepared conventionally by dry blending. For example, the blended composition of the actives and excipients may be compacted into a slug or a sheet, and then comminuted into compacted granules.
The compacted granules may subsequently be compressed into a tablet.
[00075] As an alternative to dry granulation, a blended composition may be compressed directly into a compacted dosage form using direct compression techniques. Direct compression produces a more uniform tablet without granules.
Excipients that are particularly well suited for direct compression tableting include microcrystalline cellulose, spray dried lactose, dicalcium phosphate dihydrate and colloidal silica. The proper use of these and other excipients in direct compression tableting is known to those in the art with experience and skill in particular formulation challenges of direct compression tableting.
[00076] A capsule filling of the present invention may comprise any of the aforementioned blends and granulates that were described with reference to tableting, however, they are not subjected to a final tableting step.
[00077] In another embodiment, the present invention provides a method of treating a patient comprising administering to a patient in need thereof a therapeutically effective amount of the above crystalline form of 0-desmethylvenlafaxine. Preferably, the patient suffers from a condition which may be treated with a norepinephrine or a serotonin re-uptake inhibitor. Such patient may be suffering from depression.
[00078] Having described the invention with reference to certain preferred embodiments, other embodiments will become apparent to one skilled in the art from consideration of the specification. The disclosures of the references referred to in this patent application are incorporated herein by reference. The invention is further defined by reference to the following examples describing in detail the process and compositions of the invention. It will be apparent to those skilled in the art that many modifications, both to materials and methods, may be practiced without departing from the scope of the invention.
EXAMPLES
[00079] The XRD diffraction was performed on Scintag X-ray powder diffractometer model X'TRA with a solid state detector. Copper radiation of 1.5418 A was used. The sample holder was a round standard aluminum sample holder with rough zero background. The scanning parameters were range: 2-40 degrees two-theta; scan mode: continuous scan; step size: 0.05 deg.; and at a rate of 5 deg/min.
Preparation of 0-desmethylvenlafaxine Example 1 [00080] A mixture of Venlafaxine (5.7g, 20.4 mmol) and L-Selectride, 1.0 M
solution in THF (61 m1, 61 mmol) was refluxed for about 48 hours. Methanol (30ml) was added dropwise to the stirred mixture at 0-5 C (ice/water bath), the mixture was evaporated under xeduced pressure and Hydrochloric acid, 5% aq. solution (125m1) was added to the residue. The mixture was extracted with Ethyl acetate (3x40m1), an aqueous layer was basified with 21% aq. solution of Sodium hydroxide to pH 11, filtered and washed with Ethyl acetate (3x30rn1) to give a residue (4.0g).
Preparation of 0-desmethylvenlafaxine crystal form A
Example 2 [00081] 5g of 0-desmethylvenlafaxine was crystallized from abs. Ethanol and washed with Heptane (3x30m1) to give 1.6g (30_0%) of O-Desmethylvenlafaxine as white crystals with mp 222.2-223 C and 99.17% purity by HPLC.
Example 3 [00082] A 500 ml flask equipped with a condenser and a mechanical stirrer was charged with 0-desmethylvenlafaxine base (17.5g) and IPA (450 ml). The mixture was heated to reflux until complete dissolution. The solution was then slowly cooled to 5 C and maintained at this temperature for 2 hours. The solid was filtered under reduced pressure and ciried overnight under vacuuixi at 60 C to get pure O-desmethylvenlafaxine base (15.63, 89.3%). BPLC analysis 99.95%
Exarnple 4 [00083] A 100 ml flask equipped with mechanical stirrer was charged with 0-desmethylvenlafaxine (1 g) and THF (100 ml) at ambient temperature for 20 minutes.
The solution was filtered and evaporated at 40 C under reduced pressure to get pure 0-desmethylvenlafaxine base form A.
Preparation of 0-desmethylvenlafaxine crystal forrn C
Example 5 [00084] O-desmethylvenlafaxine Succinate (0.5g, form II) and toluene (7.5m1) were put in 25m1 flask with magnetic stirrer. The suspension was heated to reflux until almost complete dissolution. The fine particles present were decanted and the clear solution was cooled to room temperature over 30 minutes to 1 hour. The solution was stirred at this temperature for ihour. The solid that appeared was then filtered under reduced pressure. The wet sample was analyzed by XRD and found to be form C. The solid was dried few hours at 50 C under vacuum and analyzed by XRD. The solid was found to be form C.
Example 6 [00085] 0.5g of O-desmethylvenlafaxine base was heated in a test tube until melting. The melted compound was then cooled to ambient temperature. The compound so-obtained was analyzed by XRD and found to be form C.
Example 7 [00086] O.Sg of 0-desmethylvenlafaxine base was heated in a test tube until melting. The melted compound was poured into ice-cold water. The compound so-obtained was analyzed by XRD and found to be form C.
Preparation of 0-desmethylvenlafaxine crystal form D
Example 8 [00087] A 100 ml flask equipped with mechanical stirrer was charged with 0-desmethylvenlafaxine (1 g) and N-methylpyrrolidinone (3 drops) at ambient temperature over week-end. The solid was then analyzed by XRD and found to be form D.
Claims (42)
1. A method of preparing a crystalline form of O-desmethylvenlafaxine characterized by X-ray powder diffraction reflections at about 12.1, 13.2, 15.9, and 20.4 degrees two theta ~ 0.2 degrees two theta comprising crystallization from a solvent selected from the group consisting of ethanol, tetrahydrofuran (THF), isopropyl alcohol (IPA) and a mixture of IPA and water.
2. The method of claim 1, wherein the solvent is absolute ethanol.
3. The method of any one of claims 1 and 2, wherein the solvent is ethanol further comprising washing with an appropriate washing liquid.
4. The method of claim 3, wherein the washing liquid is a C5-C8 hydrocarbon.
5. The method of claim 4, wherein the washing liquid is heptane.
6. The method of any one of claims 1 to 5, wherein crystallization comprises a) combining O-desmethylvenlafaxine starting material and a solvent selected from the group consisting of ethanol, tetrahydrofuran (THF), isopropyl alcohol (IPA) and a mixture of IPA and water to form a mixture;
b) heating the mixture at a temperature and for a sufficient period to obtain dissolution; and c) recovering the crystalline O-desmethylvenlafaxine.
b) heating the mixture at a temperature and for a sufficient period to obtain dissolution; and c) recovering the crystalline O-desmethylvenlafaxine.
7. The method of claim 6, wherein the mixture is heated to a temperature of about 50°C to about 100°C.
8. The method of claim 7, wherein the mixture is heated to a temperature of about 60°C to about 80°C.
9. The method of claim 6, wherein the heating step comprises refluxing for a sufficient time to effect complete dissolution of the O-desmethylvenlafaxine starting material.
10. The method of claim 6, wherein the heating step comprises evaporating the solvent.
11. The method of any one of claims 1 to 10, wherein the crystalline form of O-desmethylvenlafaxine is further characterized by a FTIR spectrum having peaks at about 844, 1276, 1517, and 1619 cm -1.
12. The method of claim 11, wherein the FTIR spectrum has further peaks at 1148, 1240, 1447, 1460, 2834, 2939 cm -1.
13. The method of claim 12, wherein the FTIR spectrum is substantially as depicted in Figure 1.
14. A crystalline form of O-desmethylvenlafaxine, characterized by X-ray powder diffraction reflections at about: 13.1, 16.2, 19.8, 20.6 and 22.2 degrees two theta ~
0.2 degrees two theta.
0.2 degrees two theta.
15. The crystalline form of O-desmethylvenlafaxine of claim 14, further characterized by X-ray powder diffraction reflections at 12.2, 15.6, and 26.2 degrees two theta ~
0.2 degrees two theta.
0.2 degrees two theta.
16. The crystalline form of O-desmethylvenlafaxine of claim 15, further characterized by the powder X-ray diffraction diagram substantially as depicted in Figure 3.
17. A crystalline form of O-desmethylvenlafaxine, characterized by X-ray powder diffraction reflections at about: 12.2, 13.3, 18.1 and 19.7 degrees two theta ~ 0.2 degrees two theta.
18. The crystalline form of O-desmethylvenlafaxine of claim 17, further characterized by X-ray powder diffraction reflections at 22.5, 25.3, and 28.7 degrees two theta ~
0.2 degrees two theta.
0.2 degrees two theta.
19. The crystalline form of O-desmethylvenlafaxine of claim 18, further characterized by the powder X-ray diffraction diagram substantially as depicted in Figure 4.
20. A method of preparing the crystalline form of O-desmethylvenlafaxine of any one of claims 14 to 17, comprising crystallizating of O-desmethylvenlafaxine from a high boiling point solvent.
21. The method of claim 20, wherein the high boiling solvent is toluene.
22. The method of any one of claims 20 and 21, comprises;
a) dissolving O-desmethylvenlafaxine or salts thereof in a high boiling point solvent by heating a suspension of starting material O-desmethylvenlafaxine in the high boiling solvent;
b) cooling the solution to a temperature of about 15°C to about 30°C;
c) maintaining the cooled solution at a temperature of about 15°C to about 30°C; and optionally d) recovering crystalline O-desmethylvenlafaxine.
a) dissolving O-desmethylvenlafaxine or salts thereof in a high boiling point solvent by heating a suspension of starting material O-desmethylvenlafaxine in the high boiling solvent;
b) cooling the solution to a temperature of about 15°C to about 30°C;
c) maintaining the cooled solution at a temperature of about 15°C to about 30°C; and optionally d) recovering crystalline O-desmethylvenlafaxine.
23. The method of claim 22, wherein the suspension is heated to reflux.
24. The method of claim 22, wherein the high boiling point solvent is toluene and the suspension is heated to a temperature 100°C to 110°C.
25. The method of any one of claims 22 to 24, wherein the starting material is a O-desmethylvenlafaxine salt.
26. The method of claim 25, wherein the O-desmethylvenlafaxine salt is the succinate salt of O-desmethylvenlafaxine.
27. The method of any one of claims 22 to 26, wherein the solution is cooled to a temperature of about 15°C to about 30°C.
28. The method of claim 27, wherein the solution is cooled to about room temperature.
29. The method of any one of claims 22 to 28, wherein the cooled solution is maintained at 15°C to about 30°C for a period of at least about
30 minutes.
30. The method of claim 29, wherein the period is about 30 minutes to about 1 hour.
30. The method of claim 29, wherein the period is about 30 minutes to about 1 hour.
31. A method of preparing the crystalline form of O-desmethylvenlafaxine of any one of claims 14 to 16, comprising heating staring material O-desmethylvenlafaxine;
and cooling the heated starting material O-desmethylvenlafaxine.
and cooling the heated starting material O-desmethylvenlafaxine.
32. The method of claim 31, wherein heating is carried out to achieve melting of the starting material O-desmethylvenlafaxine.
33. The method of any one of claims 31 and 32, wherein cooling the heated starting material is to a temperature of about 0°C to about room temperature.
34. A method of preparing the crystalline form of O-desmethylvenlafaxine of any one of claims 17 to 19, comprising suspending O-desmethylvanlafaxine in N-methylpyrrolidinone (NMP) to obtain the crystalline form of O-desmethylvenlafaxine.
35. The method of claim 34, wherein crystalline O-desmethylvenlafaxine is suspended in NMP.
36. The method of any one of claims 34 and 35, wherein the O-desmethylvenlafaxine is suspended at a temperature of about 15°C to about 30°C.
37. The method of claim 36, wherein O-desmethylvenlafaxine starting material is wetted with NMP at about room temperature for a period of about 24 to about 48 hours.
38. A pharmaceutical composition comprising at least one of the crystalline forms of O-desmethylvenlafaxine selected from the group consisting of the crystalline form of O-desmethylvenlafaxine of any one of claims 14 to 16 and the crystalline form of O-desmethylvenlafaxine of any one of claims 17 to 19, and a pharmaceutically acceptable excipient.
39. A process for preparing a pharmaceutical composition comprising mixing at least one the crystalline forms of O-desmethylvenlafaxine selected from the group consisting of the crystalline form of O-desmethylvenlafaxine of any one of claims 14 to 16 and the crystalline form of O-desmethylvenlafaxine of any one of claims 18 to 17, and a pharmaceutically acceptable excipient.
40. A pharmaceutical formulation comprising at least one of the crystalline forms of O-desmethylvenlafaxine prepared according to the processes any one of the preceding claims, and a pharmaceutically acceptable excipient.
41. A process for preparing a pharmaceutical formulation comprising mixing at least one of the crystalline forms of O-desmethylvenlafaxine prepared according to the processes of any one of the preceding claims, and a pharmaceutically acceptable excipient.
42. A method of treating a patient comprising administering to a patient in need thereof a therapeutically effective amount of one of the crystalline forms of O-desmethylvenlafaxine selected from the group consisting of the crystalline form of O-desmethylvenlafaxine of any one of claims 14 to 16 and the crystalline form of O-desmethylvenlafaxine of any one of claims 17 to 19.
Applications Claiming Priority (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79280106P | 2006-04-17 | 2006-04-17 | |
US60/792,801 | 2006-04-17 | ||
US79673906P | 2006-05-01 | 2006-05-01 | |
US60/796,739 | 2006-05-01 | ||
US87295506P | 2006-12-04 | 2006-12-04 | |
US60/872,955 | 2006-12-04 | ||
US89916607P | 2007-02-01 | 2007-02-01 | |
US60/899,166 | 2007-02-01 | ||
US90241807P | 2007-02-20 | 2007-02-20 | |
US60/902,418 | 2007-02-20 | ||
US90398807P | 2007-02-27 | 2007-02-27 | |
US60/903,988 | 2007-02-27 | ||
PCT/US2007/009560 WO2007120925A2 (en) | 2006-04-17 | 2007-04-17 | Crystal forms of o-desmethylvenlafaxine |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2649076A1 true CA2649076A1 (en) | 2007-10-25 |
Family
ID=38511422
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002649076A Abandoned CA2649076A1 (en) | 2006-04-17 | 2007-04-17 | Crystal forms of o-desmethylvenlafaxine |
Country Status (8)
Country | Link |
---|---|
US (3) | US20080015259A1 (en) |
EP (1) | EP2007709A2 (en) |
JP (1) | JP2008546719A (en) |
KR (3) | KR20080032031A (en) |
CA (1) | CA2649076A1 (en) |
IL (1) | IL194141A0 (en) |
MX (1) | MX2007016179A (en) |
WO (1) | WO2007120925A2 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008035369A2 (en) * | 2006-06-30 | 2008-03-27 | Alembic Limited | Novel form of o-desmethyl venlafaxine |
WO2009027766A2 (en) * | 2006-12-22 | 2009-03-05 | Medichem, S.A. | New crystalline solid forms of o-desvenlafaxine base |
EP2200968A1 (en) * | 2007-10-26 | 2010-06-30 | Generics Ýuk¨Limited | Process for preparing o-desmethylvenlafaxine |
EP2085377A1 (en) | 2008-01-29 | 2009-08-05 | LEK Pharmaceuticals D.D. | Novel salts of O-desmethyl-venlafaxine |
US20100016638A1 (en) * | 2008-07-21 | 2010-01-21 | Zdenko Hamersak | Method for preparation of o-desmethylvenlafaxine using polythiolates |
EP2191822A1 (en) | 2008-11-26 | 2010-06-02 | LEK Pharmaceuticals d.d. | Controlled release pharmaceutical compositions comprising O-desmethyl-venlafaxine |
CZ301503B6 (en) | 2008-11-27 | 2010-03-24 | Zentiva, A. S. | Process for preparing desvenlafaxine and salts thereof |
CZ302145B6 (en) | 2009-07-15 | 2010-11-10 | Zentiva, K. S. | Process for preparing desvenlafaxine and salts thereof |
KR20200013105A (en) | 2009-11-27 | 2020-02-05 | 젠자임 코포레이션 | An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase |
US8933123B2 (en) | 2010-10-08 | 2015-01-13 | Cadila Healthcare Limited | Polymorphic forms of O-desmethyl-venlafaxine succinate |
US9007961B2 (en) | 2010-11-22 | 2015-04-14 | May Patents Ltd. | Apparatus and method for using and solving linear programming problem and applications thereof |
CN114478271A (en) * | 2021-12-13 | 2022-05-13 | 植恩生物技术股份有限公司 | Preparation method of desvenlafaxine succinate |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE56324B1 (en) | 1982-12-13 | 1991-06-19 | American Home Prod | Phenethylamine derivatives and intermediates therefor |
US4535186A (en) * | 1983-04-19 | 1985-08-13 | American Home Products Corporation | 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives |
US6197828B1 (en) | 1998-12-01 | 2001-03-06 | Sepracor, Inc. | Derivatives of (+)-venlafaxine and methods of preparing and using the same |
WO2000059851A1 (en) | 1999-04-06 | 2000-10-12 | Sepracor Inc. | Derivatives of venlafaxine and methods of preparing and using the same |
US20020022662A1 (en) | 1999-06-15 | 2002-02-21 | American Home Products Corporation | Enantiomers of O-desmethyl venlafaxine |
MXPA03007043A (en) | 2001-02-12 | 2003-11-18 | Wyeth Corp | Novel succinate salt of o-desmethyl-venlafaxine. |
US6504044B2 (en) * | 2001-02-28 | 2003-01-07 | Council Of Scientific And Industrial Research | Process for the preparation of 1-[cyano(aryl)methyl] cyclohexanol |
US6350912B1 (en) * | 2001-02-28 | 2002-02-26 | Council Of Scientific And Industrial Research | One pot process for the preparation of 1-[2-dimethylamino-(4-methoxyphenyl)-ethyl]cyclohexanol |
KR20030000217A (en) | 2001-06-22 | 2003-01-06 | 와이어쓰 | Process for the preparation of cyclohexanol derivatives |
UA80543C2 (en) * | 2001-12-04 | 2007-10-10 | Wyeth Corp | Method for the preparation of o-desmethylvenlafaxine |
CA2482569C (en) * | 2002-03-26 | 2010-11-09 | Nicholas Piramal India Limited | Manufacture of phenyl ethylamine compounds, in particular venlafaxine |
CN1232501C (en) * | 2002-11-29 | 2005-12-21 | 重庆凯林制药有限公司 | Preparing technology for cyclohexanol derivatives used to prepare the intermediate of Venlafaxine |
TWI306092B (en) | 2003-03-11 | 2009-02-11 | Wyeth Corp | Process for preparation of phenethylamine derivatives |
WO2005049560A2 (en) | 2003-09-29 | 2005-06-02 | Sun Pharmaceutical Industries Limited | Process for the preparation of anti-depressant compound |
JP2009501229A (en) | 2005-07-15 | 2009-01-15 | ワイス | Highly selective serotonin and norepinephrine double reuptake inhibitors and uses thereof |
CA2629609A1 (en) | 2005-12-05 | 2007-06-14 | Wyeth | Process for selective synthesis of enantiomers of substituted 1-(2-amino-1-phenyl-ethyl)-cyclohexanols |
EP1973866A1 (en) * | 2005-12-20 | 2008-10-01 | Synthon B.V. | Process for making desvenlafaxine |
CA2646368A1 (en) | 2006-04-17 | 2007-10-25 | Teva Pharmaceutical Industries Ltd. | Substantially pure o-desmethylvenlafaxine and processes for preparing it |
EP1870395A1 (en) | 2006-06-19 | 2007-12-26 | KRKA, D.D., Novo Mesto | Process for preparation of o-desmethylvenlafaxine and its analogue |
US20080221356A1 (en) * | 2006-07-26 | 2008-09-11 | Valerie Niddam-Hildesheim | Processes for the synthesis of O-desmethylvenlafaxine |
KR101019454B1 (en) * | 2006-07-26 | 2011-03-07 | 테바 파마슈티컬 인더스트리즈 리미티드 | Processes for the synthesis of o-desmethylvenlafaxine |
US20090137846A1 (en) * | 2006-07-26 | 2009-05-28 | Valerie Niddam-Hildesheim | Processes for the synthesis of O-Desmethylvenlafaxine |
WO2008013995A2 (en) | 2006-07-26 | 2008-01-31 | Teva Pharmaceutical Industries Ltd. | Tridesmethylvenlafaxine and processes for the synthesis of o-desmethylvenlafaxine |
US20100121108A1 (en) | 2006-08-04 | 2010-05-13 | Medichem, S.A. | Process for synthesizing desvenlafaxine free base and salts or solvates thereof |
-
2006
- 2006-06-22 MX MX2007016179A patent/MX2007016179A/en unknown
-
2007
- 2007-04-17 EP EP07755729A patent/EP2007709A2/en not_active Withdrawn
- 2007-04-17 KR KR1020077029445A patent/KR20080032031A/en not_active Application Discontinuation
- 2007-04-17 US US11/788,030 patent/US20080015259A1/en not_active Abandoned
- 2007-04-17 WO PCT/US2007/009560 patent/WO2007120925A2/en active Application Filing
- 2007-04-17 CA CA002649076A patent/CA2649076A1/en not_active Abandoned
- 2007-04-17 JP JP2008517242A patent/JP2008546719A/en active Pending
- 2007-04-17 KR KR1020107000134A patent/KR20100010948A/en active IP Right Grant
- 2007-04-17 US US11/788,034 patent/US7674935B2/en not_active Expired - Fee Related
- 2007-04-17 KR KR1020077029493A patent/KR100958156B1/en not_active IP Right Cessation
-
2008
- 2008-09-16 IL IL194141A patent/IL194141A0/en unknown
-
2009
- 2009-08-03 US US12/462,482 patent/US20090292142A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR100958156B1 (en) | 2010-05-18 |
EP2007709A2 (en) | 2008-12-31 |
US7674935B2 (en) | 2010-03-09 |
US20080033051A1 (en) | 2008-02-07 |
JP2008546719A (en) | 2008-12-25 |
US20080015259A1 (en) | 2008-01-17 |
MX2007016179A (en) | 2008-03-11 |
KR20080032032A (en) | 2008-04-14 |
US20090292142A1 (en) | 2009-11-26 |
WO2007120925A3 (en) | 2008-01-17 |
KR20100010948A (en) | 2010-02-02 |
WO2007120925A2 (en) | 2007-10-25 |
IL194141A0 (en) | 2009-08-03 |
KR20080032031A (en) | 2008-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7674935B2 (en) | Crystal forms of O-desmethylvenlafaxine | |
US7563930B2 (en) | Crystal forms of Cinacalcet HCI and processes for their preparation | |
EP2007708A1 (en) | Substantially pure o-desmethylvenlafaxine and processes for preparing it | |
EP2016045A2 (en) | Tigeycline crystalline forms and processes for preparation thereof | |
US20120122915A1 (en) | Crystalline forms of palonosetron hydrochloride | |
WO2009017813A1 (en) | O-desmethyl venlafaxine saccharinate | |
EP1866275A1 (en) | Crystalline forms of pregabalin | |
US20040235904A1 (en) | Crystalline and amorphous solids of pantoprazole and processes for their preparation | |
US20090012182A1 (en) | Crystal forms of O-desmethylvenlafaxine succinate | |
US20230339962A1 (en) | Solid state forms of sep-363856 and process for preparation thereof | |
US20220356165A1 (en) | Solid state forms of roluperidone and salts thereof | |
US20060270684A1 (en) | Crystalline forms of ziprasidone mesylate | |
US20080027128A1 (en) | Duloxetine HCL polymorphs | |
WO2021133811A1 (en) | Solid state forms of cenicriviroc and process for preparation thereof | |
WO2008088900A2 (en) | Polymorphic forms of rimonabant base and processes for preparation thereof | |
BRPI0702870A2 (en) | processes for preparing a crystalline form of o-demethylvenlafaxine, therapeutic composition therewith and method of treating a patient in need thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |